[1] Normanno N, Morabito A, De Luca A, et al. Target-based therapies in breast cancer: current status and future perspectives[J]. Endocr Relat Cancer, 2009, 16 (3): 675.
[2] Aesoy R, Sanchez BC, Norum JH, et al. An autocrine VEGF/VEGFR-2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells[J]. Mol Cancer Res, 2008, 6 (10): 1630.
[3] Le XF, Mao W, Lu C, et al. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2[J]. Cell Cycle, 2008, 7 (23): 3747.
[4] Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances[J]. Oncologist, 2005, 10 (6): 382.
[5] Cesare G, PaoloM, Antonio R, et al. The role of bevacizumab in the treatment of non-small cell lung cancer: current Indications and future developments[J]. The Oncologist, 2007, 12 (10) : 1183.
[6] Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for matastatic breast cancer[J]. N Engl J Med, 2007, 357 (26): 2666.
[7] Park JW,Neve RM, Szollosi J,et al. Unraveling the biologic and clinical comp lexities of HER2[J]. Clin Breast Cancer, 2008, 8 (5) : 392.
[8] Freudenberg JA,Wang Q, Katsumata M, et al. The role of HER2 in early breast cancermetastasis and the origins of resistance to HER2-targeted therapies[J]. Exp Mol Pathol, 2009, 87 (1) : 1.
[9] SpectorNL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor-2 positive breast cancer[J]. J Clin Oncol, 2009, 27 (34) : 5838.
[10] Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies[J]. Lancet Oncol, 2009, 10 (12) : 1179.
[11] Modi S, Sugarman S, Stopeck A, et al. Phase II trial of the HSP90 inhibitor tanesp imycin (Tan) + trastuzumab (T) in patients ( pts) with HER2-positive metastatic breast cancer (MBC) [J]. J ClinOncol, 2008, 26 (5) : 1027.
[12] Mulik RS, Mnkknen J, Juvonen RO, et al. Transferrin mediated solid lipid nanoparticles containing curcumin: Enhanced in vitro anticancer activity by induction of apoptosis[J]. Int J Pharm, 2010, 398 (1-2): 190.
[13] Zheng Y, Yu B, Weecharangsan W,et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7α-APTADD to breast cancer cells[J]. Int J Pharm, 2010, 390 (2): 234.
[14] Acharya S,Dilnawaz F, Sahoo SK, et al. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy[J]. Biomaterials, 2009, 30 (29): 5737.
[15] Yu DH, Lu Q, Xie J, et al. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature[J]. Biomaterials, 2010, 31 (8): 2278.
[16] Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening[J]. Cell, 2009, 138 (4): 645.
[17] Riccioni R, Dupuis ML, Bernabei M, et al. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor[J]. Blood Cells Mol Dis, 2010, 45 (1): 86.
[18] Fuchs D, Heinold A, Opelz G, et al. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells[J]. Biochem Biophys Res Commun, 2009 , 390 (3): 743.
[19] Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancercells to chemotherapy[J]. J Natl Cancer Inst, 2008, 100 (9): 672.
[20] Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses[J]. Breast Cancer Res Treat, 2008, 112: 533.
[21] Liu Y, Lu WL, Guo J, et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes[J] J Control Release, 2008, 129 (1): 18.
[22] Zhou J, Zhang H, Gu P, et al. NF-kB pathway inhibitors preferentially inhibit breast cancer stem-like cells[J]. Breast Cancer Res Treat, 2008, 111 (3): 419.
[23] Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission[J]. Cancer Res, 2009, 69 (19): 7507.
[24] Anisimov VN, Egormin PA, Piskunova TS, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo[J]. Cell Cycle, 2010, 9 (1): 188.
[25] Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells[J]. Cell Cycle, 2009, 8(13): 2031.
[26] Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci USA, 2003, 100 (7): 3983.
[27] Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics[J]. Breast Cancer Res, 2008, 10 (1): R10.
[28] Hwang-Verslues WW, Kuo WH, Chang PH, et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers[J]. PLoS One, 2009, 4 (12): e8377.
[29] Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome[J]. Cell Stem Cell, 2007, 1 (5): 555.
[30] Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content[J]. Cell, 2010, 40 (1): 62.